Invitrogen to Present at UBS Global Life Sciences Conference

CARLSBAD, Calif.--(BUSINESS WIRE)--Sept. 27, 2005--Invitrogen Corporation (Nasdaq:IVGN), announced today that Gregory T. Lucier, Invitrogen's Chairman and CEO, will present at the UBS Global Life Sciences Conference in New York City, New York today, September 27 at 11:00 a.m. Eastern Time. Mr. Lucier's presentation will be webcast and available for viewing live and after the conference on Invitrogen's website www.invitrogen.com in the Investor Relations section of the site.

About Invitrogen Corporation

Invitrogen Corporation (Nasdaq:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, bioinformatics and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California and conducts business in more than 70 countries around the world. The company globally employs approximately 4,500 scientists and other professionals and had revenues of more than $1 billion in 2004. For more information about Invitrogen, visit the company's web site at www.invitrogen.com.